Friday, 23 July 2021 06:42 GMT

Global Rare Hemophilia Factors Market Research Report 2021: Market to Surpass $350 Million by 2027 - Fresh Frozen Plasma to Account for 168.1 Million of the Total Market


(MENAFN - PR Newswire) DUBLIN, July 21, 2021 /PRNewswire/ -- The "Rare Hemophilia Factors - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Global Rare Hemophilia Factors Market to Reach $350.8 Million by 2027 Amid the COVID-19 crisis, the global market for Rare Hemophilia Factors estimated at US$252.3 Million in the year 2020, is projected to reach a revised size of US$350.8 Million by 2027, growing at a CAGR of 4.8% over the analysis period 2020-2027.

Fresh Frozen Plasma, one of the segments analyzed in the report, is projected to record a 4.7% CAGR and reach US$168.1 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Factor Concentrates segment is readjusted to a revised 5.6% CAGR for the next 7-year period. The U.S. Market is Estimated at $74.3 Million, While China is Forecast to Grow at 4.6% CAGR The Rare Hemophilia Factors market in the U.S. is estimated at US$74.3 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$62.3 Million by the year 2027 trailing a CAGR of 4.6% over the analysis period 2020 to 2027.

Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.4% and 4.1% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.6% CAGR. Cryoprecipitate Segment to Record 4.2% CAGR In the global Cryoprecipitate segment, USA, Canada, Japan, China and Europe will drive the 4.4% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$34.6 Million in the year 2020 will reach a projected size of US$46.6 Million by the close of the analysis period.

China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$39.3 Million by the year 2027. Key Topics Covered: I. METHODOLOGY II. EXECUTIVE SUMMARY 1. MARKET OVERVIEW

  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS (Total 40 Featured)

  • Baxalta
  • Bayer healthcare
  • Bio Products Laboratory Ltd
  • Biogen
  • CSL Behring
  • Novo Nordisk
  • Pfizer, Inc.
  • Shire
  • Takeda Pharmaceutical Co. Ltd.

3. MARKET TRENDS & DRIVERS 4. GLOBAL MARKET PERSPECTIVE

  • World Current & Future Analysis for Rare Hemophilia Factors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • World Historic Review for Rare Hemophilia Factors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • World 15-Year Perspective for Rare Hemophilia Factors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
  • World 15-Year Perspective for Fresh Frozen Plasma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • World 15-Year Perspective for Factor Concentrates by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • World 15-Year Perspective for Cryoprecipitate by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • World 15-Year Perspective for Other Treatments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

  • United States
  • Canada
  • Japan
  • China
  • Europe
  • France
  • Germany
  • Italy
  • United Kingdom
  • Spain
  • Russia
  • Rest Of Europe
  • Asia-Pacific
  • Australia
  • India
  • South Korea
  • Rest Of Asia-Pacific
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Rest Of Latin America
  • Middle East
  • Iran
  • Israel
  • Saudi Arabia
  • United Arab Emirates
  • Rest Of Middle East
  • Africa

IV. COMPETITION

  • Total Companies Profiled: 40

For more information about this report visit

Media Contact:

Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

Modal title

MENAFN21072021003732001241ID1102489680


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.